Fundz

SciRhom raised $70M in a Series A funding round led by Andera Partners, Kurma Partners, Hadean Capital, MIG Capital and Wellington Partners to bring its first drug prospect into human testing.

PRIVATEJul 09, 2024

Amount Raised

$70 Million

Round Type

Series A

MunichBiotechnologyHealth CareTherapeuticsBiopharma

Investors

Wellington PartnersMIG CapitalHadean CapitalKurma PartnersAndera Partners

Description

SciRhom, a German biotechnology startup focused on autoimmune diseases, has raised a $70 million Series A funding round to support the development of antibody drugs aimed at evaluating in inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease.

Quick answer

SciRhom GmbH raised $70 Million in a Series A round, dated July 9, 2024. Investors: Wellington Partners, MIG Capital, Hadean Capital, Kurma Partners and Andera Partners. SciRhom GmbH is based in Munich, Bavaria, Germany.

How much did SciRhom GmbH raise?
SciRhom GmbH raised $70 Million in a Series A round on July 9, 2024.
Who invested in SciRhom GmbH?
Wellington Partners, MIG Capital, Hadean Capital, Kurma Partners and Andera Partners are named as investors in this round.
What does SciRhom GmbH do?
SciRhom GmbH is a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, with a mission to provide a new treatment paradigm for autoimmune diseases.
Where is SciRhom GmbH based and how big is it?
SciRhom GmbH is based in Munich, Bavaria, Germany. Fundz records about 11 employees.
Who are the decision-makers at SciRhom GmbH?
Fundz holds 1 contact at SciRhom GmbH. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at SciRhom GmbH, and when

A new round usually means SciRhom GmbH is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day SciRhom GmbH raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at SciRhom GmbH, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at SciRhom GmbH. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

SciRhom GmbH

Location

Munich, Bavaria, Germany

About

SciRhom GmbH is a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, with a mission to provide a new treatment paradigm for autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment SciRhom GmbH raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for SciRhom GmbH's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

SciRhom GmbH raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.